Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,030.00    5.00 (0.08%)
Bid:
6,025.00
Ask:
6,035.00
Spread: 10.00 (0.166%)
Market Cap: £5.15b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

RULE 38.5_A - DCC Plc

1 May 2026 10:02

RNS Number : 8010C
Morgan Stanley Europe SE
01 May 2026
 

 

FORM 38.5(a) (EPT/RI)

 

IRISH TAKEOVER PANEL

 

DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISHTAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022BY A CONNECTED EXEMPT PRINCIPAL TRADER WITHRECOGNISED INTERMEDIARY STATUS AND DEALING INA CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

 

(a) Name of exempt principal trader:

Morgan Stanley Europe SE

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

DCC Plc

(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1)

Energy Capital Partners, LLC and Kohlberg Kravis Roberts & Co. L.P

(d) Date dealing undertaken:

30 April 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

 

 

(a) Purchases and sales

 

Class of relevant security (Note 3)

Purchases/ sales

Totalnumber of securities

Highest price per unit paid/ received

Lowest price per unit paid/ received

0.25 ordinary shares

PURCHASES

10,672

57.8483 GBP

55.4000 GBP

0.25 ordinary shares

SALES

10,672

57.3850 GBP

55.4000 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities (Note 4)

Price perunit (Note 5)

N/A

N/A

N/A

N/A

N/A

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 4)

Exercise price per unit

Type  e.g. American, European etc.

Expirydate

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii) Exercise

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise priceper unit (Note 5)

N/A

N/A

N/A

N/A

N/A

 

(d) Other dealings (including transactions in respect of new securities)

 

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

N/A

N/A

N/A

N/A

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

 

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

NONE

 

Date of disclosure:

01 May 2026

Contact name:

Claire Gordon

Telephone number:

+44 141 245-8893

 

Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPUARKRNAUVRRR
Date   Source Headline
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1
4th Feb 20207:00 amRNSInterim Management Statement
17th Jan 20209:23 amRNSHolding in Company TR-1
3rd Jan 202010:03 amRNSHolding in Company - TR1
23rd Dec 201912:44 pmRNSHolding in Company TR-1
5th Dec 20195:44 pmRNSHolding in Company - TR1
29th Nov 20191:39 pmRNSTotal Voting Rights
27th Nov 20199:18 amRNSDirector Declaration
18th Nov 20196:14 pmRNSDirector/PDMR Shareholding
12th Nov 20197:00 amRNSResults for the six months ended 30 September 2019
12th Nov 20197:00 amRNSDCC Healthcare acquires Ion Laboratories
7th Nov 201911:30 amRNSHolding in Company TR-1
23rd Oct 20192:25 pmRNSHolding in Company TR-1
21st Oct 20195:01 pmRNSHolding in Company TR-1
18th Oct 20194:46 pmRNSHolding in Company TR-1
17th Oct 20199:43 amRNSHolding in Company TR-1
25th Sep 20195:39 pmRNSHolding in Company TR-1
4th Sep 20199:57 amRNSHolding in Company TR-1
9th Aug 201910:42 amRNSHolding in Company TR-1
7th Aug 20199:23 amRNSHolding in Company TR-1
31st Jul 20192:58 pmRNSTotal Voting Rights
16th Jul 20196:14 pmRNSDirector/PDMR Shareholding
12th Jul 20193:06 pmRNSResult of AGM
12th Jul 20197:00 amRNSInterim Management Statement
5th Jul 20199:06 amRNSHolding in Company TR-1
19th Jun 20199:22 amRNSHolding in Company TR-1
13th Jun 201911:37 amRNS2019 Annual Report, Notice of AGM and Proxy Form
31st May 20199:47 amRNSTotal Voting Rights
28th May 20197:00 amRNSHolding in Company TR-1
23rd May 20196:25 pmRNSDirector/PDMR Shareholding
22nd May 20199:43 amRNSHolding in Company TR-1
16th May 20199:03 amRNSHolding in Company TR-1
14th May 20197:01 amRNSDCC Development Update
14th May 20197:00 amRNSResults for the year ended 31 March 2019
13th May 201910:14 amRNSBoard Change
28th Mar 20198:47 amRNSDirector Declaration
28th Feb 20199:00 amRNSTotal Voting Rights
5th Feb 20197:00 amRNSInterim Management Statement
1st Feb 20194:25 pmRNSHolding in Company TR-1
25th Jan 20193:12 pmRNSHolding in Company TR-1
22nd Jan 20192:27 pmRNSHolding in Company TR-1
10th Jan 201912:58 pmRNSHolding in Company TR-1
2nd Jan 20193:07 pmRNSHolding in Company TR-1
14th Dec 201811:50 amRNSHolding in Company TR-1
12th Dec 20189:08 amRNSHolding in Company TR-1
30th Nov 20183:03 pmRNSTotal Voting Rights
29th Nov 20184:50 pmRNSHolding in Company TR-1
19th Nov 20186:01 pmRNSHolding in Company TR-1
19th Nov 20185:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.